Patents Awarded to Metabolon for Metabolomics Methods
News Apr 01, 2010
Metabolon, Inc. has announced the grant of US Patent 7,682,783 and US Patent 7,682,784 entitled “Methods for Drug Discovery, Disease Treatment and Diagnosis Using Metabolomics”.
The USPTO awarded the patents to Metabolon on March 23, 2010. The issued claims in the new patents are for uses of metabolomics to identify diagnostic biomarkers for depression and schizophrenia by profiling classes of metabolites in a sample.
The innovations provide means to identify novel metabolite biomarkers for depression or schizophrenia by profiling the biochemicals, such as sugars, nucleotides, fatty acids, amino acids and other small molecules, in patient samples and then comparing the profiles with reference profiles. These profiles and biomarkers can be developed into diagnostic tests for these mental disorders. In addition, the biomarkers can be used in drug development to monitor clinical trials.
Metabolon is the exclusive license holder of the Daouk-Kristal patent family which is comprised of early, pioneering patents and patent applications which provide fundamental IP in the field of metabolomics. The ‘783 and ’784 patents are the seventh and eighth patents to issue from the Daouk-Kristal family.
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
'Body-on-a-Chip' Could Advance Drug EvaluationNews
MIT engineers have developed new technology that could be used to evaluate new drugs and detect possible side effects before the drugs are tested in humans. Using a microfluidic platform that connects engineered tissues from up to 10 organs, the researchers can accurately replicate human organ interactions for weeks at a time.READ MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.